MAMohammad Almermesh

Mohammad Almermesh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Almermesh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Value of the Lactate-to-Albumin and C-Reactive Protein-to-Albumin Ratios in COVID-19–Associated ARDS

    by Sultan Almuntashiri, Yazeed Adel M. Alsubhi, Ziyad Khalid B. Alhelali, Abdulrahman Fraih M. Alanazi, Meshari Mohammed B. Alamri, Bader M. Alshoumr, Saleh Alghamdi, Mohammad Hajaj Said Almermesh, Talib Hussain, Sirajudheen Anwar

    Background: Coronavirus disease 2019 (COVID-19) is frequently complicated by acute respiratory distress syndrome (ARDS), which is associated with high mortality. The lactate-to-albumin ratio (LAR) and C-reactive protein-to-albumin ratio (CAR) have been proposed as prognostic markers in critical illness, but their comparative performance in COVID-19–associated ARDS is not well established. Methods: We conducted a retrospective cohort study using the MIMIC-IV database, which contains data from Beth Israel Deaconess Medical Center, United States, including COVID-19 ICU admissions from 2020 to 2022. Adult COVID-19 patients with available PaO2/FiO2, lactate, albumin, and C-reactive protein measurements within the first 48 h of ICU admission were included. Receiver operating characteristic analysis, Kaplan–Meier survival analysis, and Cox proportional hazards regression were performed. Results: Of the 3620 patients screened, 66 met the inclusion criteria; 36 survived and 30 died. Non-survivors had significantly higher LAR and CAR values at ICU admission. In ROC analyses, LAR demonstrated moderate discrimination for 30-day mortality (AUC 0.706) and showed higher discriminatory performance than CAR in most subgroup analyses. Among ARDS patients, LAR showed moderate predictive ability (AUC 0.693), compared with CAR (AUC 0.655). In severe ARDS, both markers demonstrated improved discrimination (0.722 AUC for LAR and 0.797 for CAR). High LAR was associated with significantly higher 30-day mortality in all ARDS patients (60.5% vs. 24.0%; p = 0.0056) and severe ARDS patients (72.0% vs. 20.0%; p = 0.0022). Elevated CAR was also associated with increased mortality, particularly in severe ARDS (73.1% vs. 14.3%; p < 0.001). In multivariable Cox regression, LAR remained independently associated with 30-day mortality. Conclusions: LAR demonstrated independent prognostic value for 30-day mortality in critically ill COVID-19 patients with ARDS. CAR showed variable performance. These readily available biomarkers, particularly LAR, may aid early risk stratification although larger studies are needed to confirm these findings.

  • Open Access

    Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention

    by Yousef M. Al-Saraireh, Fatemah O. F. O. Alshammari, Omar H. Abu-Azzam, Sa’ed M. Al-Dalain, Yahya M. Al-Sarayra, Mansour Haddad, Hafiz Makeen, Aiman Al-Qtaitat, Mohammad Almermesh, Sameeh A. Al-Sarayreh

    Over the past decade, there have been significant developments in treatment for ovarian cancer, yet the lack of targeted therapy with few side effects still represents a major issue. The cytochrome P450 (CYP) enzyme family plays a vital role in the tumorigenesis process and metabolism of drugs and has a negative impact on therapy outcomes. Gaining more insight into CYP expression is crucial to understanding the pathophysiology of ovarian cancer since many isoforms are essential to the metabolism of xenobiotics and steroid hormones, which drive the disease’s development. To the best of our knowledge, no review articles have documented the intratumoral expression of CYPs and their implications in ovarian cancer. Therefore, the purpose of this review is to provide a clear understanding of differential CYP expression in ovarian cancer and its implications for the prognosis of ovarian cancer patients, together with the effects of CYP polymorphisms on chemotherapy metabolism. Finally, we discuss opportunities to exploit metabolic CYP expression for the development of novel therapeutic methods to treat ovarian cancer.


  • Open Access

    Targeting Cytochrome P450 Enzymes in Ovarian Cancers: new approaches for Tumour-Selective Interventions

    by Yousef M. Al-Saraireh, Fatemah O. F. O. Alshammari, Omar H. Abu-Azzam, Sa’Ed M. Al-Dalain, Yahya M. Al-Sarayra, Mansour Haddad, Hafiz Makeen, Aiman Al-Qtaitat, Mohammad Almermesh, Sameeh A. Al-Sarayreh

    Over the past decade, significant developments have occurred in treatment strategies for ovarian cancer, yet targeted therapy with few side effects is still a major issue. The cytochrome P450 (CYP) enzyme family plays a vital role in the tumorigenesis process and metabolism of drugs, with a negative impact on therapy outcomes. Gaining more insight into CYP expression is crucial for understanding the pathophysiology of ovarian cancer since many isoforms are essential for the metabolism of xenobiotics and steroid hormones, which drive the disease's development. The purpose of this review is to provide a clear understanding of differential CYP expression in ovarian cancer and its implications for the prognosis of ovarian cancer patients, together with their polymorphisms' effect on chemotherapy metabolism. Finally, we provide our thoughts on opportunities to exploit metabolic CYP expression for novel therapeutic development to treat ovarian cancer.